Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC31892Decursin ((+)-Decursin)CAS: 5928-25-6纯度: >98.00%
A phytochemical with diverse biological activities
- GC32186Puromycin (CL13900)CAS: 53-79-2纯度: {{1-12}>98.00%}
Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
- GC32587Clofilium tosylateCAS: 92953-10-1纯度: >98.00%
Clofiliumtosylate是一种钾通道(potassiumchannel)阻滞剂,作用于人早幼粒细胞白血病(HL-60)细胞,激活caspase-3而诱导凋亡。具有抗心律失常作用。
- GC32681GSK2795039CAS: 1415925-18-6纯度: >99.50% / >98.00%
GSK2795039是一种强效NADPH氧化酶2(NOX2)抑制剂,IC 50 值为0.18μM。
- GC32692APTO-253 (LOR-253)CAS: 916151-99-0纯度: >98.00%
APTO-253 是一种新型小分子,通过诱导 Kruppel 样因子 4 (KLF4) 主转录因子基因表达,从而抑制细胞周期并导致程序性细胞死亡,发挥强大的抗肿瘤活性。
- GC32704Atezolizumab (MPDL3280A)CAS: 1380723-44-3纯度: >98.50% / >99.00% / >95.00%
Atezolizumab 是一种针对 PD-L1 的特异性单克隆抗体,可以抑制 PD-L1 和 PD-1 之间的结合。
- GC32708Forodesine hydrochloride (BCX-1777)CAS: 284490-13-7纯度: >99.50%
A nucleoside analog and PNP inhibitor
- GC32710GDC-0077 (RG6114)CAS: 2060571-02-8纯度: >98.00% / >99.00%
GDC-0077 (RG6114)是一种高效且选择性的PI3Kα抑制剂,IC 50 值为0.038nM。
- GC32723CDDO-Im (RTA-403)CAS: 443104-02-7纯度: >98.00%
CDDO-Im (RTA-403)是一种合成三萜类化合物,通过与Kelch样ECH相关蛋白1(Keap1)结合抑制核因子E2相关因子(Nrf2)的降解,从而激活Nrf2信号通路并提高其蛋白水平。
- GC32724LW6 (HIF-1α inhibitor)CAS: 934593-90-5纯度: >98.00%
LW6是一种缺氧诱导因子1(hypoxia inducing factor 1, HIF)抑制剂,通过降解HIF-1α有效抑制HIF-1α的积累,但不影响缺氧时HIF- 1a mRNA水平。
- GC32729Rhosin hydrochlorideCAS: 1281870-42-5纯度: >99.50% / >98.00%
Rhosin hydrochloride是一种有效的、特异性的RhoA亚家族Rho GTPases小分子抑制剂,能够特异性地结合RhoA并抑制RhoA与鸟嘌呤核苷酸交换因子(GEF)的相互作用,其解离常数(Kd)约为0.4μM。
- GC32737TAK-243 (MLN7243)CAS: 1450833-55-2纯度: >98.00%
TAK-243 (MLN7243)是一种选择性泛素活化酶(UBA1)抑制剂,IC 50 值为1nM。
- GC32762Icaritin (Anhydroicaritin)CAS: 118525-40-9纯度: >99.00%
Icaritin (Anhydroicaritin)是从中药淫羊藿中提取的天然黄酮类化合物。Icaritin (Anhydroicaritin)常用于抗癌、骨骼保护、抗炎、神经保护、心血管保护和抗病毒等领域的研究。
- GC32775RIP2 kinase inhibitor 1CAS: 1423186-80-4纯度: >98.50%
GSK2983559 active metabolite is an active metabolite of GSK2983559, also is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC31892 | Decursin ((+)-Decursin) | 5928-25-6 | >98.00% | |
A phytochemical with diverse biological activities | ||||
| GC32066 | RRx-001 | 925206-65-1 | >99.50% | |
RRx-001 是一种源自航空航天的抗癌剂,具有产生活性氮物质 (RNS) 的化学作用,可导致表观遗传改变,例如癌细胞中的 DNA 甲基化和组蛋白乙酰化。 | ||||
| GC32127 | Alofanib (RPT835) | 1612888-66-0 | >98.50% | |
An allosteric inhibitor of FGFR2 | ||||
| GC32138 | Furazolidone | 67-45-8 | >98.00% | |
A nitrofuran antiprotozoal and antibacterial agent | ||||
| GC32186 | Puromycin (CL13900) | 53-79-2 | {{1-12}>98.00%} | |
Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor. | ||||
| GC32280 | HS-1371 | 2158197-70-5 | >97.00% | |
A RIPK3 inhibitor | ||||
| GC32391 | Pyrogallol | 87-66-1 | >99.50% | |
A natural oxidant | ||||
| GC32587 | Clofilium tosylate | 92953-10-1 | >98.00% | |
Clofiliumtosylate是一种钾通道(potassiumchannel)阻滞剂,作用于人早幼粒细胞白血病(HL-60)细胞,激活caspase-3而诱导凋亡。具有抗心律失常作用。 | ||||
| GC32681 | GSK2795039 | 1415925-18-6 | >99.50% / >98.00% | |
GSK2795039是一种强效NADPH氧化酶2(NOX2)抑制剂,IC 50 值为0.18μM。 | ||||
| GC32687 | Takinib | 1111556-37-6 | >98.00% | |
A TAK1 inhibitor | ||||
| GC32692 | APTO-253 (LOR-253) | 916151-99-0 | >98.00% | |
APTO-253 是一种新型小分子,通过诱导 Kruppel 样因子 4 (KLF4) 主转录因子基因表达,从而抑制细胞周期并导致程序性细胞死亡,发挥强大的抗肿瘤活性。 | ||||
| GC32695 | Ac-DEVD-CHO | 169332-60-9 | >98.00% | |
Ac-DEVD-CHO是一种Caspase-3抑制剂,IC 50 值为0.016μM。 | ||||
| GC32704 | Atezolizumab (MPDL3280A) | 1380723-44-3 | >98.50% / >99.00% / >95.00% | |
Atezolizumab 是一种针对 PD-L1 的特异性单克隆抗体,可以抑制 PD-L1 和 PD-1 之间的结合。 | ||||
| GC32708 | Forodesine hydrochloride (BCX-1777) | 284490-13-7 | >99.50% | |
A nucleoside analog and PNP inhibitor | ||||
| GC32710 | GDC-0077 (RG6114) | 2060571-02-8 | >98.00% / >99.00% | |
GDC-0077 (RG6114)是一种高效且选择性的PI3Kα抑制剂,IC 50 值为0.038nM。 | ||||
| GC32719 | dBET6 | 1950634-92-0 | >99.50% | |
dBET6是一种新型的、具有口服活性的BRD4降解剂,可抑制c-Myc等致癌基因的转录和表达。 | ||||
| GC32723 | CDDO-Im (RTA-403) | 443104-02-7 | >98.00% | |
CDDO-Im (RTA-403)是一种合成三萜类化合物,通过与Kelch样ECH相关蛋白1(Keap1)结合抑制核因子E2相关因子(Nrf2)的降解,从而激活Nrf2信号通路并提高其蛋白水平。 | ||||
| GC32724 | LW6 (HIF-1α inhibitor) | 934593-90-5 | >98.00% | |
LW6是一种缺氧诱导因子1(hypoxia inducing factor 1, HIF)抑制剂,通过降解HIF-1α有效抑制HIF-1α的积累,但不影响缺氧时HIF- 1a mRNA水平。 | ||||
| GC32729 | Rhosin hydrochloride | 1281870-42-5 | >99.50% / >98.00% | |
Rhosin hydrochloride是一种有效的、特异性的RhoA亚家族Rho GTPases小分子抑制剂,能够特异性地结合RhoA并抑制RhoA与鸟嘌呤核苷酸交换因子(GEF)的相互作用,其解离常数(Kd)约为0.4μM。 | ||||
| GC32737 | TAK-243 (MLN7243) | 1450833-55-2 | >98.00% | |
TAK-243 (MLN7243)是一种选择性泛素活化酶(UBA1)抑制剂,IC 50 值为1nM。 | ||||
| GC32753 | Taltobulin (HTI-286) | 228266-40-8 | >99.50% | |
An inhibitor of microtubule polymerization | ||||
| GC32762 | Icaritin (Anhydroicaritin) | 118525-40-9 | >99.00% | |
Icaritin (Anhydroicaritin)是从中药淫羊藿中提取的天然黄酮类化合物。Icaritin (Anhydroicaritin)常用于抗癌、骨骼保护、抗炎、神经保护、心血管保护和抗病毒等领域的研究。 | ||||
| GC32767 | 3BDO | 890405-51-3 | >98.00% / >96.00% | |
A butyrolactone derivative and autophagy inhibitor | ||||
| GC32775 | RIP2 kinase inhibitor 1 | 1423186-80-4 | >98.50% | |
GSK2983559 active metabolite is an active metabolite of GSK2983559, also is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1. | ||||
